Helix Biopharma Corp Stock Price Prediction
| HBPCF Stock | USD 1.73 0.00 0.00% |
Momentum 100
Buy Peaked
Oversold | Overbought |
Using Helix BioPharma hype-based prediction, you can estimate the value of Helix BioPharma Corp from the perspective of Helix BioPharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Helix BioPharma to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Helix because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Helix BioPharma after-hype prediction price | USD 1.73 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Helix |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Helix BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Helix BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Helix BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Helix BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Helix BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Helix BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Helix BioPharma's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Helix BioPharma's historical news coverage. Helix BioPharma's after-hype downside and upside margins for the prediction period are 0.09 and 25.27, respectively. We have considered Helix BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Helix BioPharma is out of control at this time. Analysis and calculation of next after-hype price of Helix BioPharma Corp is based on 3 months time horizon.
Helix BioPharma Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Helix BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Helix BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Helix BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.94 | 23.54 | 0.00 | 4.17 | 0 Events / Month | 0 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.73 | 1.73 | 0.00 |
|
Helix BioPharma Hype Timeline
Helix BioPharma Corp is currently traded for 1.73. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 4.17. Helix is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 2.94%. %. The volatility of related hype on Helix BioPharma is about 1657.75%, with the expected price after the next announcement by competition of 5.90. About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.04. Helix BioPharma Corp had not issued any dividends in recent years. Assuming the 90 days horizon the next forecasted press release will be in a few days. Check out Helix BioPharma Basic Forecasting Models to cross-verify your projections.Helix BioPharma Related Hype Analysis
Having access to credible news sources related to Helix BioPharma's direct competition is more important than ever and may enhance your ability to predict Helix BioPharma's future price movements. Getting to know how Helix BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Helix BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RLFTY | Relief Therapeutics Holding | 0.00 | 0 per month | 10.05 | 0.07 | 9.59 | (7.41) | 132.30 | |
| CLTEF | Calliditas Therapeutics AB | 0.00 | 0 per month | 0.00 | 0.17 | 27.27 | (36.76) | 58,052 | |
| PSYBF | PsyBio Therapeutics Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RLFTF | Relief Therapeutics Holding | 0.00 | 0 per month | 10.91 | 0.04 | 10.91 | (9.19) | 78.78 | |
| ACHFF | Arch Biopartners | 0.00 | 0 per month | 0.00 | (0.11) | 3.03 | (7.61) | 19.05 | |
| INNMF | Amplia Therapeutics Limited | 0.00 | 0 per month | 9.92 | 0.05 | 29.87 | (16.67) | 128.67 | |
| ZIVO | Zivo Bioscience | 0.00 | 11 per month | 0.00 | (0.04) | 16.92 | (20.26) | 53.18 | |
| TCNAF | TransCanna Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OTLC | Oncotelic Therapeutics | 14.20 | 1 per month | 4.90 | 0.05 | 14.29 | (10.00) | 36.11 | |
| VICP | Vicapsys Life Sciences | 0.00 | 0 per month | 0.00 | (0.17) | 0.00 | 0.00 | 15.25 |
Helix BioPharma Additional Predictive Modules
Most predictive techniques to examine Helix price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Helix using various technical indicators. When you analyze Helix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Helix BioPharma Predictive Indicators
The successful prediction of Helix BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Helix BioPharma Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Helix BioPharma based on analysis of Helix BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Helix BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Helix BioPharma's related companies.
Story Coverage note for Helix BioPharma
The number of cover stories for Helix BioPharma depends on current market conditions and Helix BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Helix BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Helix BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Complementary Tools for Helix Pink Sheet analysis
When running Helix BioPharma's price analysis, check to measure Helix BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helix BioPharma is operating at the current time. Most of Helix BioPharma's value examination focuses on studying past and present price action to predict the probability of Helix BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helix BioPharma's price. Additionally, you may evaluate how the addition of Helix BioPharma to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |